Famotidine Relieves Symptoms of Gastroesophageal Reflux Disease and Heals Erosions and Ulcerations: Results of a Multicenter, Placebo-Controlled, Dose-Ranging Study

Archives of Internal Medicine

Volumn 151, Issue 12, 1991, Pages 2394-2400

  Sabesin, Seymour M ^a   Berlin, Roger G ^b,c   Humphries, Thomas J ^c   Bradstreet, Deborah C ^b   Walton Bowen, Karen L ^b   Zaidi, Syed ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTACID AGENT; ATTAPULGITE; FAMOTIDINE; MAGNESIUM TRISILICATE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS ULCER; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WOUND HEALING;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ESOPHAGOSCOPY; FAMOTIDINE; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MALE; MIDDLE AGE; PATIENT COMPLIANCE; SUPPORT, NON-U.S. GOV'T;

EID: 0026333490     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1991.00400120040007     Document Type: Article

References (24)

1. Graham DY, Smith JL, Patterson DJ. Why do apparently healthy people use antacid tablets? Am J Gastroenterol. 1983;78:257-260.
2. Nebel OT, Forbes MF, Castell DO. Symptomatic GE reflux: incidence and precipitating factors. Am J Dig Dis. 1976;21:953-956.
3. Graham DY, Patterson DJ. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis. Dig Dis Sci. 1983:559-566.
4. Orr WC, Robinson MG, Woodruff DM, Allen ML, Humphries TJ. Validation of an ambulatory pH monitoring system. Gastroenterology. 1986;90:A1575. Abstract.
5. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988;95:903-912.
6. Castell DO. Medical therapy esophagitis. Ann Intern Med. 1980;93:926-927.
7. Hogan WJ. Gastroesophageal reflux disease: an update on management. J Clin Gastroenterol. 1990;12(suppl 2):S21-S28.
8. Koelz HR. Treatment of reflux esophagitis with H2blockers, antacids and prokinetic drugs. Scand J Gastroenterol. 1989;24(suppl 156):25-36.
9. Palmer RH, Frank WO, Rockhold FW, Wetherington JD, Young MD. Cimetidine 800 mg twice daily for healing erosions and ulcers in gastroesophageal reflux disease. J Clin Gastroenterol. 1990(suppl 2):S29-S34.
10. Sontag S, Robinson M, McCallum RW, Barwick KW, Nardi R. Ranitidine therapy for gastroesophageal reflux disease. Arch Intern Med. 1987;147:1485-1489.
11. Johnson NJ, Boyd EJS, Mills JG, Wood JR. Acute treatment of reflux esophagitis: a multicenter trial to compare 150 mg ranitidine b.d. with 300 mg ranitidine q.d.s. Aliment Pharmacol Ther. 1989;3:259-266.
12. Simon TJ, Berlin RG, Stien DT, et al. BID regimens of H2receptor antagonists heal erosive esophagitis: US trial. Gastroenterology. 1990;98:A21. Abstract.
13. Simon TJ, Berlin RG, Tipping RW, Stauffer LA, Gilde LR. Results of an international multi-center trial comparing b.i.d. dosing to H2-receptor antagonists. Am J Gastroenterol. 1990;85:A1225
14. Hirchowitz B, Holt S, Robinson M, et al. Omeprazole is superior to placebo in the complete relief of heartburn and endoscopic healing in patients with reflux esophagitis. Am J Gastroenterol. 1989;84:A1144
15. Bate CM, Keeling PW, O’Morain C, et al. Comparison of omeprazole and cimetidine in reflux esophagitis. Gut. 1990;31:968-972.
16. Bardham KD, Morris P, Thompson M, et al. Omeprazole in the treatment of erosive esophagitis refractory to high dose cimetidine and ranitidine. Gut. 1990;31:745-749.
17. Vantrappen G, Rutgeerts L, Schurmans P, Coenegraghts JL. Omeprazole (40 mg) is superior to ranitidine in short term treatment of ulcerative reflux esophagitis. Dig Dis Sci. 1988;33:523-529.
18. Fink SM, McCallum RW. The role of prolonged esophageal pH monitoring in the diagnosis of GERD. JAMA. 1984;252:1160-1164.
19. Rokkas T, Sladen GE. Ambulatory esophageal pH recording in GE reflux: relevance to development of esophagitis. Am J Gastroenterol. 1988;83:629-632.
20. Meuwissen SGM, Klinkenberg-Knol EC. Treatment of reflux esophagitis with H2RA. Scand J Gastroenterol. 1988;23(suppl 146):201-213.
21. Wiener GJ, Morgan TM, Cooper JB, et al. Ambulatory 24-hour pH monitoring. Dig Dis Sci. 1988;33:1127-1133.
22. Chremos AN. Clinical pharmacology of famotidine. J Clin Gastroenterol. 1987;9(suppl 2):7-12.
23. Savarino V, Picciotto A, Magnolia MR, Scalabrini P, Mela GS, Celle G. Single bedtime dose of famotidine: assessment of its antisecretory action by 24-hour monitoring. J Clin Pharmacol. 1987;27:790-793.
24. Lanzon-Miller S, Pounder RE, Ball SG, Dalgleish DJ, Coward J, Jackson AO. The effect of famotidine 40 mg at night on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects. Scand J Gastroenterol. 1988;23:244-250.